144 related articles for article (PubMed ID: 31369545)
1. Cost-effectiveness of measles treatment: a systematic review.
Vo NX; Van Nguyen AT; Mai Tran HT; Thuy Truong LT; Bao Nguyen NN
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S148-S154. PubMed ID: 31369545
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
Bawa S; Wondimu A; Postma MJ; Hutubessy R; van Hulst M
Expert Rev Vaccines; 2024; 23(1):655-673. PubMed ID: 38924461
[TBL] [Abstract][Full Text] [Related]
3. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
5. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
Wichmann O; Ultsch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
[TBL] [Abstract][Full Text] [Related]
7. The average cost of measles cases and adverse events following vaccination in industrialised countries.
Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
[TBL] [Abstract][Full Text] [Related]
9. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions.
Thompson KM; Odahowski CL
Risk Anal; 2016 Jul; 36(7):1297-314. PubMed ID: 25545778
[TBL] [Abstract][Full Text] [Related]
11. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
[TBL] [Abstract][Full Text] [Related]
12. A benefit-cost analysis of two-dose measles immunization in Canada.
Pelletier L; Chung P; Duclos P; Manga P; Scott J
Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
[TBL] [Abstract][Full Text] [Related]
13. Future savings from measles eradication in industrialized countries.
Carabin H; Edmunds WJ
J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
[TBL] [Abstract][Full Text] [Related]
14. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
15. Measles and Measles Vaccination: A Review.
Bester JC
JAMA Pediatr; 2016 Dec; 170(12):1209-1215. PubMed ID: 27695849
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella Vaccination to Prevent Measles Importations Among International Travelers From the United States.
Hyle EP; Fields NF; Fiebelkorn AP; Walker AT; Gastañaduy P; Rao SR; Ryan ET; LaRocque RC; Walensky RP
Clin Infect Dis; 2019 Jul; 69(2):306-315. PubMed ID: 30312374
[TBL] [Abstract][Full Text] [Related]
18. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
19. [35-year measles, mumps, rubella vaccination assessment in France].
Reinert P; Soubeyrand B; Gauchoux R
Arch Pediatr; 2003 Nov; 10(11):948-54. PubMed ID: 14613687
[TBL] [Abstract][Full Text] [Related]
20. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
Bart KJ; Orenstein WA; Hinman AR
Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]